Susquehanna International Group’s bioAffinity Technologies BIAFW Stock Holding History

Susquehanna International Group’s Portfolio BIAFW Stock Details BIAFW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55K	Buy	11,180 +167	+2%	+$43	﹤0.01%	13234
2026 Q1	$3.63K	Buy	+11,013	New	+$3.49K	﹤0.01%	12999
2023 Q4	–	Sell	-10,525	Closed	-$961	–	12351
2023 Q3	$961	Buy	+10,525	New	+$3.14K	﹤0.01%	11878
2023 Q2	–	Sell	-14,077	Closed	-$4.22K	–	12072
2023 Q1	$4.22K	Sell	14,077 -13,071	-48%	-$4.88K	﹤0.01%	12323
2022 Q4	$11.4K	Buy	27,148 +963	+4%	+$424	﹤0.01%	11914
2022 Q3	$9K	Buy	+26,185	New	+$27.1K	﹤0.01%	12792

Other funds holding BIAFW

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group's BIAFW Position: Q2 2026 in Review

Susquehanna International Group increased its bioAffinity Technologies (BIAFW) stake by 1.5% in Q2 2026, buying an estimated $43 and bringing the position to 11,180 shares worth $1.55K. The position accounts for ﹤0.01% of the portfolio, ranked #13234.

Susquehanna International Group first reported a position in BIAFW in Q3 2022 and has held it in 6 quarters since. The position peaked at $11.4K in Q4 2022. 4 funds tracked by Wall St. Rank hold BIAFW as of Q2 2026.

Susquehanna International Group held 11,180 shares of bioAffinity Technologies worth $1.55K as of Q2 2026.
Susquehanna International Group bought 167 bioAffinity Technologies shares in Q2 2026, an estimated $43.
bioAffinity Technologies made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #13234 holding.
Susquehanna International Group first reported a position in bioAffinity Technologies in Q3 2022 and has held it in 6 quarters since.
Susquehanna International Group's bioAffinity Technologies position peaked at $11.4K in Q4 2022.
4 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.